One of the most common questions patients have when starting pembrolizumab is: how long will I be on treatment? The answer depends on your cancer type, how you respond, and whether side effects occur - but there are clear frameworks that guide treatment duration decisions.
The standard maximum duration
For most pembrolizumab indications in advanced cancer, treatment continues for a maximum of approximately two years (35 cycles at the three-weekly schedule, or 18 cycles at the six-weekly schedule). This is not a rigid rule - it reflects the duration of treatment in the pivotal clinical trials that established pembrolizumab's efficacy, and the current evidence base for how long treatment needs to continue to achieve lasting benefit.
In the adjuvant setting (after surgery to reduce recurrence risk), treatment courses are typically defined as one year.
Stopping treatment for response
Some patients achieve a confirmed complete response - no detectable tumour on imaging - before reaching the two-year mark. Guidelines generally recommend stopping treatment after a sustained complete response has been confirmed, with continued monitoring. The data suggests that stopping pembrolizumab after a documented complete response does not significantly increase the risk of relapse compared to continuing.
Stopping treatment for progression or toxicity
Treatment is also stopped if the cancer progresses despite pembrolizumab, if an immune-related adverse event requires permanent discontinuation, or if the patient chooses to stop. Progression on pembrolizumab does not mean all options are exhausted - it may open eligibility for subsequent treatment lines.
For immune-related adverse events, the decision to permanently stop versus temporarily pause (hold) depends on the severity and type of irAE. Many irAEs resolve with steroid treatment and allow pembrolizumab to resume; a minority require permanent discontinuation.
After treatment ends
Patients who complete a full two-year course of pembrolizumab while responding continue on surveillance - regular imaging and clinical review to detect any recurrence early. Some patients remain in sustained remission for years after completing treatment. If the disease does recur after a treatment-free interval, re-treatment with pembrolizumab may be considered, depending on the circumstances and the reason for the original treatment stop.
Thinking about what a treatment commitment looks like?
Duration and scheduling are covered in detail on the Welcome Call. Start with the eligibility check - it takes three minutes.
Check your eligibility